Hypertension is among the most common etiological factors of heart failure with preserved ejection fraction (HFpEF), where pressure overload of the left ventricle leads to its eccentric hypertrophy and diastolic dysfunction. According to recent study results, empagliflozin significantly reduces the risk of cardiovascular (CV) complications in patients with HFpEF. The EMPEROR-Preserved sub-analysis further examined the impact of baseline systolic blood pressure (sBP) on treatment outcomes and patient prognosis.
Patients with HF with left ventricular ejection fraction (LVEF) > 40% were included in the randomized double-blind study. The patients were divided into 2 groups in a 1 : 1 ratio. The first group received empagliflozin in a dose of 10 mg daily in addition to their chronic medication, while the second group received a placebo. Patients with and without diabetes (DM) were included. At each doctor's visit, patients’ blood pressure was measured, vital functions were monitored, estimated glomerular filtration rate (eGFR) was determined, adverse effects of treatment were recorded, changes in chronic medication were noted, and the overall condition of the patient was assessed. Administration of empagliflozin or placebo was discontinued at the end of the study, and patients underwent a follow-up check-up after 23–45 days.
The primary efficacy endpoint comprised the first hospitalization for heart failure (HF) or death from CV causes, and the time to this event was determined. Secondary endpoints included all potential hospitalizations related to HF and changes in eGFR.
For the analysis, patients were divided into 3 groups based on baseline sBP values: 130 mmHg. The influence of baseline BP on the later occurrence of hypotension, symptomatic hypotension, acute renal failure, and hypovolemia was also examined.
A total of 5,988 patients were included in the study, with 2,997 receiving empagliflozin and 2,991 receiving a placebo. It was shown that patients with lower baseline BP were at a more advanced stage of HF. These patients had higher levels of NT-proBNP, heart rate, albuminuria, lower eGFR, higher probability of hospitalization for HF in the last 12 months, and higher prevalence of diabetes.
In the placebo group, the incidence of the primary endpoint in the case of sBP > 130 mmHg was 8.58/100 patient-years, in the 110–130 mmHg group it was 8.26/100 patient-years, and among patients with sBP 130 mmHg group (p = 0.008).
In the group with sBP 130 mmHg, a decrease in BP was also observed in both treatment arms. Patients receiving empagliflozin experienced fewer adverse effects and instances of acute renal failure. Hypovolemia and symptomatic hypotension were numerically more frequent in those taking empagliflozin, especially in those with baseline sBP
The risk of death from CV causes and HF hospitalization was lower in the group receiving empagliflozin, regardless of baseline BP. This was also true for the time to the first hospitalization for HF.
In the group of patients with lower baseline sBP (
According to the results of this study, baseline sBP cannot be considered a factor modifying the cardio-renal effectiveness and mechanism of action of empagliflozin. Its effect is preserved even at sBP 40%.
(kali)
Source: Böhm M., Anker S., Mahfoud F. et al. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J 2023 Feb 1; 44 (5): 396–407, doi: 10.1093/eurheartj/ehac693.
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
